Zhejiang Cancer Hospital

A novel molecular classification system based on feature scores identifies four HCC clusters: C1 (high TP53 mutations, immune suppression, responsive to anti-PD1 therapy), C2 (high tumor purity, cold immunity), C3 (early phase, favorable prognosis), and C4 (late phase, poor prognosis). FTCD is identified as a classification-specific prognostic gene with tumor-suppressing roles, particularly for C1 and C4 patients.

EVER-132-002 study, compliant with Helsinki and ICH GCP guidelines, was approved by national authorities and ethics committees. It enrolled HR+HER2- metastatic or locally recurrent BC patients from China, Korea, and Taiwan, requiring prior chemotherapy and measurable disease. Patients were randomized 1:1 to receive SG or chemotherapy, with PFS as the primary endpoint. Secondary endpoints included OS, ORR, DoR, CBR, safety, and QoL. Assessments involved tumor measurements, safety evaluations, and QoL questionnaires. Statistical analysis included sample size calculation, HR estimation, and safety summaries. The study design details are available in the Nature Portfolio Reporting Summary.

Kuick Research predicts the first CD47 targeting drug will be approved by 2029. The report highlights global market opportunities, insights on over 100 CD47 inhibitor drugs in clinical trials, and key developments in CD47 inhibitor drugs. CD47-targeted therapies aim to enhance the immune system's natural defense against cancer cells, with multiple antibodies in development. The CD47 market is expanding rapidly due to the rising incidence of cancer and increased clinical research.

Summit Therapeutics presented ivonescimab data at ESMO 2024, showing efficacy in TNBC, HNSCC, and MSS CRC, with plans to expand clinical development beyond metastatic NSCLC.

Ivonescimab shows promising anti-tumor activity and safety in CRC, TNBC, and HNSCC, with encouraging Phase II data supporting its clinical development expansion beyond metastatic NSCLC, as presented at ESMO 2024.